Moberg Pharma AB (publ) operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Moberg Pharma AB (publ) with three other
pharmaceutical manufacturers in Europe:
Horizon Discovery Group PLC
of the United Kingdom
sales of £58.73 million [US$76.18 million]
of which 79%
New Nordic Healthbrands AB
(393.71 million Swedish Kronor [US$40.83 million]
Venture Life Group plc
based in the United Kingdom
(£18.77 million [US$24.35 million]
of which 65%
was Development and Manufacturing).
Moberg Pharma AB (publ) reported sales of SEK 439.04 million (US$45.53 million)
December of 2018.
a very small
increase of 0.0%
versus 2017, when the company's sales were SEK 439.03 million.
Sales at Moberg Pharma AB (publ) have increased during each of the previous five years
(and since 2013, sales have increased a total of 179%).
Sales of Dermoplast saw an increase
that was more than double the company's growth rate: sales were up
22.2% in 2018, from
SEK 96.59 million to SEK 117.98 million.
Moberg Pharma AB (publ) also saw significant increases in sales in
Kerasal Nail /nalox (up 14.5% to SEK 175.89 million)
New Skin (up 7.2% to SEK 94.11 million)
Not all segments of Moberg Pharma AB (publ) experienced an increase in sales in 2018:
sales of Divested Products (Jointflex , Fergon , fell 76.1% to SEK 8.38 million.
Moberg Pharma AB (publ) also experienced decreases in sales in
Other Products (down 35.2% to SEK 42.68 million)